Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

被引：0

作者：

Labidi-Galy, S. I. ^{[1
]}

Rouge, T. deLa Motte ^{[2
]}

Derbel, O. ^{[3
]}

Wolfer, A. ^{[4
]}

Kalbacher, E. ^{[5
]}

Olivier, T. ^{[1
]}

Combes, J-D. ^{[6
]}

Hu-Heimgartner, K. ^{[1
]}

Tredan, O. ^{[7
]}

Guevara, H. ^{[7
]}

Heinzelmann-Schwarz, V. ^{[8
]}

Fehr, M. ^{[9
]}

de Castelbajac, V. ^{[10
]}

Vaflard, P. ^{[11
]}

Crivelli, L. ^{[12
]}

Bonadona, V. ^{[7
]}

Viassolo, V. ^{[1
]}

Bazan, F. ^{[13
]}

Rodrigues, M. ^{[14
]}

Ray-Coquard, I. L. ^{[7
]}

机构：

[1] HUG, Dept Oncol, Geneva, Switzerland

[2] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[3] Hop Prive Jean Mermoz, Inst Canc, Lyon, France

[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[5] CHRU Besancon, Hop Jean Minjoz, Dept Oncol, Besancon, France

[6] IARC, Infect & Canc Epidemiol Grp, Lyon, France

[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[8] Univ Spital Basel, Dept Gynecol, Basel, Switzerland

[9] Kantonsspital Frauenfeld, Frauenklin, Frauenfeld, Switzerland

[10] Inst Curie, Dept Oncol, Paris, France

[11] Inst Curie, Dept Med Oncol, Paris, France

[12] Ctr Eugene Marquis, Div Canc Genet, Rennes, France

[13] CHU Besancon, Hop Jean Minjoz, Doubs, Besancon, France

[14] Inst Curie, Dept Med Oncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1003P

引用

页码：410 / 410

页数：1

共 50 条

[1] Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Labidi-Galy, S. Intidhar
Rouge, Thibault de La Motte
Derbel, Olfa
Wolfer, Anita
Kalbacher, Elsa
Olivier, Timothee
Combes, Jean-Damien
Heimgartner-Hu, Ketty
Tredan, Olivier
Guevara, Hemerson
Heudel, Pierre-Etienne
Reverdy, Thibaut
Bazan, Fernando
Heinzelmann-Schwarz, Viola
Fehr, Mathias
de Castelbajac, Victoire
Vaflard, Pauline
Crivelli, Louise
Bonadona, Valerie
Viassolo, Valeria
Buisson, Adrien
Golmard, Lisa
Rodrigues, Manuel
Ray-Coquard, Isabelle
GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 262 - 269
[2] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
Lieberman, Howard B.
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
[3] Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.
Labidi-Galy, Sana Intidhar
Rouge, Thibault De La Motte
Derbel, Olfa
Kalbacher, Elsa
Wolfer, Anita
Olivier, Timothee
Hu, Ketty
Tredan, Olivier
Guevara, Hemerson
Bazan, Fernando
De Castelbajac, Victoire
Combes, Jean-Damien
Vaflard, Pauline
Crivelli, Louise
Bonadona, Valerie
Viassolo, Valeria
Golmard, Lisa
Buisson, Adrien
Rodrigues, Manuel
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
Kim, Ji Hyun
Kim, Se Ik
Park, Eun Young
Kim, Eun Taeg
Kim, Hyesu
Kim, Sangeon
Park, Sang-Yoon
Lim, Myong Cheol
GYNECOLOGIC ONCOLOGY, 2024, 181 : 33 - 39
[5] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Cho, Angela
Park, Jeong-Yeol
Lee, Shin-Wha
Kim, Dae-Yeon
Suh, Dae-Shik
Kim, Jong-Hyeok
Kim, Yong-Man
Kim, Young-Tak
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
[6] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Angela Cho
Jeong-Yeol Park
Shin-Wha Lee
Dae-Yeon Kim
Dae-Shik Suh
Jong-Hyeok Kim
Yong-Man Kim
Young-Tak Kim
Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
[7] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
Saleh, Naveed
Copur, Mehmet Sitki
ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
[8] Olaparib Maintenance Therapy in BRCA-positive Ovarian Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03)
[9] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
Torres Toala, F. G.
Solorzano, J.
Baldi, J.
VALUE IN HEALTH, 2018, 21 : S22 - S22
[10] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PANAMA
Torres Toala, F. G.
Solorzano, J.
Baldi, J.
Castillo-Fernandez, O.
VALUE IN HEALTH, 2018, 21 : S22 - S22

← 1 2 3 4 5 →